Journal Information
Vol. 93. Issue 4.
Pages 236-241 (01 October 2020)
Vol. 93. Issue 4.
Pages 236-241 (01 October 2020)
Original Article
DOI: 10.1016/j.anpede.2019.12.012
Open Access
Supraventricular tachycardia in children from the perspective of a specialised between-hospital transport team
Taquicardia paroxística supraventricular desde la perspectiva del transporte interhospitalario
Anna Sabaté Rotésa, Marc Figueras Colla,b, Ferran Gran Ipiñaa, Alba Gallardo-Caleroa,b,c,d,e, Luis Renter Valdovinosc,d, Pedro Domínguez-Sampedrod, Ferran Rosés-Noguera,e,
Corresponding author

Corresponding author.
a Servicio de Cardiología Pediátrica, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
b Unidad de Cardiología Pediátrica, Hospital Universitari Josep Trueta, Girona, Spain
c Unidad de Cuidados Intensivos Pediátricos, Servicio de Pediatría, Hospital Parc Taulí, Sabadell, Barcelona, Spain
d Unidad de Trasporte Pediátrico, Hospital Universitario Vall d’Hebron, Sistema de Emergencias Médicas de Catalunya, Barcelona, Spain
e Paediatric Cardiology Department, Royal Brompton and HarefieldNHS Foundation Trust, Chelsea, Londres, United Kingdom
Article information
Full Text
Download PDF
Tables (3)
Table 1. Demographic, clinical and aetiological characteristics.
Table 2. Summary of treatments performed.
Table 3. Analysis of risk factors for haemodynamic instability.
Show moreShow less

The aim of this study is to establish the incidence of supraventricular tachycardia (SVT) as a main reason for between-hospital transfer in children, as well as to describe the clinical presentation, prognosis and treatment, risk factors presenting with haemodynamic compromise, and to propose a specific management protocol for the transport.


A retrospective observational study was conducted on all patients with supraventricular tachycardia transferred by the Hospital Vall d’Hebron Sistema de Emergencias Médicas Pediátricas (SEM-P) between January 2005 and June 2017.


During the study period, 67 (0.9%) patients (out of a total number of 7348 transfers) suffered from SVT. The median age was 57 days (2 h-18 years old). There was clinical evidence of cardiogenic shock on admission in 14 (20.9%) patients. Age ≤1 year was the only independent risk factor associated with presenting with cardiogenic shock on admission, with an OR of 10.2 (95% CI: 1.2–89.9; p = 0.004). The majority of patients could be treated appropriately by the local hospital team, except for oral intubation and cardioversion that were performed mainly by the transport team on arrival at the local hospital. Median stabilisation time was 35 min (9–169), and median total transport time was 30 min (9–165).


Only 0.9% of transport cases are due to SVT, but this can be highly demanding as patients can be critically ill. Age ≤1 year was the only independent risk factor associated with presenting with cardiogenic shock on admission. Coordination between the local and the transport teams is crucial for a good clinical outcome.

Supraventricular tachycardia
Emergency care
Paediatrictransport carepaediatrics

Determinar la frecuencia de taquicardia paroxística supraventricular (TPSV) como motivo de traslado interhospitalario en la edad pediátrica, describir la forma de presentación clínica, evolución y tratamiento, y factores de riesgo de presentar compromiso hemodinámico y proponer un protocolo de manejo específico para el transporte.


Estudio retrospectivo observacional de los pacientes atendidos en el Sistema de Emergencias Médicas Pediátricas (SEM-P) del Hospital Vall d’Hebron entre enero 2005 y junio 2017.


De un total de 7.348 traslados, 67 fueron pacientes con TPSV (0,9%). Edad mediana de 57 días de vida (2 h a 18 años). Catorce pacientes (20,9%), presentaban signos de compromiso hemodinámico en el momento del diagnóstico. La edad ≤1 año fue el único factor de riesgo independiente para presentar compromiso hemodinámico al diagnóstico con un OR de 10,2 (IC 95%: 1,2–89,9; p: 0,004). La mayoría de pacientes revirtieron con las intervenciones del hospital emisor, exceptuando la intubación y la cardioversión eléctrica, realizadas más frecuentemente por el equipo de trasporte (ET). El tiempo mediano de estabilización fue de 35 min (9–169), con un tiempo mediano de traslado de 30 min (9–165).


El transporte de pacientes pediátricos con TPSV es poco frecuente, pero puede requerir un manejo altamente especializado. La edad ≤1 año es el único factor de riesgo independiente para presentar compromiso hemodinámico. La coordinación entre el equipo del hospital emisor y el ET es de gran importancia para un buen resultado asistencial.

Palabras clave:
Taquicardia paroxística supraventricular
Full Text

Paroxysmal supraventricular tachycardia (PSVT) is the most frequent form of arrhythmia in the paediatric age group following sinus tachycardia.1 The underlying mechanisms of PSVT involve a pattern of reentry or the presence of arrhythmias due to enhanced abnormal automaticity, which are referred to as ectopic or focal tachycardias. In young children, tachycardias due to accessory pathways are most frequent (80%), but in adolescence the proportion is reversed, and nodal reentrant tachycardias become more frequent.2,3 In the group of reentrant tachycardias, we ought to specifically mention permanent junctional reciprocating tachycardia (PJRT), also known as Coumel’s tachycardia, because while it is a reentrant tachycardia it is caused by an occult accessory pathway typically located in the posterior septal portion of the tricuspid ring with properties of decremental conduction that produce a characteristic electrocardiographic pattern with a prolonged RP interval and negative P waves in the inferior leads. This form of tachycardia is relevant because it is particularly frequent in infants and usually has onset with tachycardiomyopathy.4 Ectopic atrial tachycardias (ATs) are relatively infrequent in children,2 amounting to approximately 10% of the total cases of PSVT according to some authors.5 Due to its abrupt onset, older patients usually can identify the exact time of onset of the tachycardia, but it may go undetected in younger patients, especially in newborns and infants, and eventually present as severe acute heart failure secondary to tachymyocardiopathy.3,6 Acute care of the episode varies depending on the level of haemodynamic instability of the patient and focuses on terminating the tachycardia and initiating supportive care to revert the haemodynamic effects of the episode, which may require mechanical ventilation, use of inotropic/diuretic agents and administration of antiarrhythmic drugs to stabilize the patient, and in some cases even cardiopulmonary resuscitation (CPR) manoeuvres. The interventions used to terminate PSVT may include vagal manoeuvres, treatment with antiarrhythmic drugs and electrical cardioversion based on the severity and mechanism of the tachycardia.7,8

The aetiology, presentation, treatment and outcomes of PSVT in paediatric patients are thoroughly described in books on paediatrics and paediatric cardiology.9,10 In the current scientific literature, there are articles on the subject of the prehospital care of PSVT in adults,11 but none specifically focused on the paediatric population. The available literature includes some prospective studies that report outcomes of PSVT management in the emergency department1,12 and others that describe the outcomes of using adenosine for its management.13,14 The Paediatric Medical Emergency System (P-MES) of Catalonia is responsible for paediatric and neonatal interhospital transport and covers the entire regions of Catalonia and Andorra, with a maximum range of action of 4 h and a radius of 300 km. It comprises 3 units: 2 land units and 1 air unit (helicopter). All units are based off the city of Barcelona. Each transport team (TT) consists of a paediatrician, a paediatric nurse and a medical transport technician.

The objectives of our study were to establish the frequency of PSVT as a reason for interhospital transport, describe the clinical presentation of PSVT, its outcomes, and its management, and analyse the risk factors associated with haemodynamic instability, with the purpose of proposing a specific protocol for the management of these patients during interhospital transport.

Patients and methods

We conducted a retrospective observational study of all patients given a final diagnosis of PSVT between January 2005 and June 2017. We retrieved data from the database of the P-MES of the Hospital Universitari Vall d’Hebron, which stores data collected prospectively in a structured and systematic fashion, collecting information for the following variables: age (newborn, ≤30 days, or child >30 days), weight, sex, previous history of tachycardia, current ongoing treatment, presence of congenital heart defects, symptoms and haemodynamic instability, mechanism of the tachycardia, type and effectiveness of treatment used to terminate the episode, severity of episode based on need for mechanical ventilation, administration of volume expanders or inotropic agents, type of vascular access, performance of CPR, time to stabilization, duration of transport and complications during transport. We did not include patients with other types of arrhythmia.

We defined haemodynamic instability as the presence of poor general condition, respiratory distress, decreased peripheral perfusion, systemic hypotension and metabolic acidosis (pH <7.35 and base excess <−5). We defined the time to stabilization as the time elapsed from the departure of the P-MES team from the referring hospital to arrival to the receiving hospital.

The descriptive analysis of the data was performed with the software SPSS® version 18.0. We expressed continuous data as mean ± standard deviation (SD) or median and range depending on whether or not they followed a normal distribution, and compared proportions with the Fisher exact test, considering differences corresponding to p-values of less than 0.05 statistically significant. To assess potential risk factors for haemodynamic instability, we performed a multivariate logistic regression with backward stepwise removal based on likelihood ratios (LRs) by applying the BSTEP-LR method.


Of a total of 7348 transports, 67 corresponded to patients with PSVT (0.9%). Table 1 summarises the demographic, clinical and aetiological characteristics of included cases. Most patients were aged 1 year or less (42; 62.7%), the male-to-female ratio was 1:1.16, and the median weight of patients was 4.8 kg (2.2–80). For most patients, this was the first episode of PSVT (64.2%).

Table 1.

Demographic, clinical and aetiological characteristics.

Variables  n or value  Percentage or range 
Female  36  53.7 
Male  31  46.7 
Median age  57 days  2 h–18 years 
Age ≤1 year  42  62.7 
Age ≤5 years  51  76.1 
Median weight, kg  4.8  2.2−80 
History of heart disease  9.0 
Previous PSVT  24  35.8 
Previous antiarrhythmic treatment  13  54.1 
Tachycardia when TT arrived to RH  22  32.8 
Mechanism of tachycardia
Reentry tachycardia with short RP interval  56  83.6 
Coumel’s reentry tachycardia with long RP interval  4.5 
Automatic atrial tachycardia  10.4 
Atrial fibrillation  1.5 
Haemodynamic instability  14  20.9 

PSVT, paroxysmal supraventricular tachycardia; RH, referring hospital; TT, transport team.

The main presenting symptom that led to diagnosis of tachycardia varied by age group. In the group of 51 patients aged less than 5 years, the most frequent symptoms were irritability with poor general health (25, 49.0%), followed by chest pain (4, 7.8%) and syncope (1, 1.9%). In the remaining 21, the diagnosis was made following incidental finding of a high heart rate (HR) in absence of any other symptoms, and in 4 cases the diagnosis was made after detection of an increased HR during a bronchitis episode. In the group of 16 patients aged more than 5 years, the symptoms that led to diagnosis were palpitation in 13 cases (81.2%), abdominal pain in 1 (6.2%), and incidental finding of increased HR in 2 (12.5%). Of all 67 patients, 14 (20.9%) presented with haemodynamic instability at the time of diagnosis. Only 6 patients (8.9%) had an underlying congenital heart defect. The underlying mechanism of PSVT was a reentrant pattern with a short RP interval in 56 (83.6%), PJRT in 3 (4.5%) and ectopic/automatic AT in 7 (10.4%). One patient had atrial fibrillation (1.5%).

Acute treatment of tachycardia

Table 2 summarises the treatments used in these patients. Of the 67 patients, 45 (67.2%) already had a sinus rhythm when the TT arrived to the referring hospital (RH), and 22 (32.8%) still had tachycardia. When it came to the treatment used to terminate tachycardia, in 7 patients (10.4%) it resolved spontaneously without intervention of the medical team. Vagal manoeuvres were performed in 37 patients (55.2%) and were only effective in 11 (16.4%). Adenosine was given to 45 patients (67.1%) and was effective in 24 (35.8%). The mean effective dose was 179 ± 75 µg/kg, with a median of 3 attempts per patient (1–4). The mean initial dose of adenosine was of 101 ± 48 µg/kg. The mean second dose of adenosine was of 145 ± 56 µg/kg. The mean third dose of adenosine was of 207 ± 87 µg/kg. None of the patients developed significant side effects. Fifteen patients (22.4%) received other antiarrhythmic drugs, which were effective in 9 (60%). Synchronised electric cardioversion was performed in 6 patients (7.5%) and effective in 4 (66.7%). After stabilization, 54 patients (80.6%) underwent transport with a sustained sinus rhythm without recurrence of tachycardia, 9 (13.4%) underwent transport with tachycardia without establishment of a sinus rhythm during the transfer, and 4 (6.0%) had multiple episodes of PSVT during transport.

Table 2.

Summary of treatments performed.

Variables  n or value  Percentage or range 
Spontaneous resolution of tachycardia  10.4 
Performance of vagal manoeuvres  37  55.2 
Effective  11  29.7 
Ineffective  26  70.3 
Who performed the vagal manoeuvres?
Referring hospital  33  89.2 
Transport team  8.1 
Both  2.7 
Administration of adenosine  45  67.2 
Effective  24  53.3 
Ineffective  21  46.7 
Who performed the adenosine stress test?
Referring hospital  36  80.0 
Transport team  13.3 
Ambos  6.7 
Administration of antiarrhythmic drugs  15  22.4 
Effective  60.0 
Ineffective  40.0 
Who administered antiarrhythmic drugs?
Referring hospital  11  73.3 
Transport team  26.7 
Synchronized cardioversion  7.5 
Effective  66.7 
Ineffective  33.3 
Who performed cardioversion?
Referring hospital  33.3 
Transport team  66.7 
Cardiopulmonary resuscitation  1.5 
Condition during transport
Sinus rhythm without recurrences  54  80.6 
Multiple recurrences  6.0 
Transport with tachycardia  13.4 
Analysis of supportive care during transport

Of the 67 patients, 58 (86.6%) underwent placement of a peripheral catheter, inserted in the RH in 52 cases (89.7%) and by the P-MES in 1 (1.7%), and in 5 cases (8.6%) they had to insert a new peripheral catheter due to extravasation of the previous catheter. Seven (10.4%) patients required mechanical ventilation, with staff in the RH performing the intubation in 3 of the patients (42.9%) and the TT in 4 (57.1%). An umbilical catheter was placed in 4 patients (6%), 3 at the RH and 1 by the TT. Five patients (7.5%) required placement of a central venous catheter, in 4 cases inserted at the RH and in only 1 case by the TT. Only 1 patient required intraosseous cannulation, which was performed by the TT. Four patients (6%) required volume expanders, administered at the RH in 2 cases and by the TT in 2. Six patients (9%) received inotropic drugs to ensure correct tissue perfusion, with inotropic support initiated at the RH in 3 cases and by the TT in the rest. Only 1 patient (1.5%) went into cardiac arrest, with CPR delivered by staff from both the RH and the TT.

In the study sample, the median time to stabilization was 35 min (9–169), and the median duration of transport 30 min (9–165). In comparison, in the total of patients transported by the P-MES in the same period, the median time to stabilization was of 35 min (14–220) and the median duration of transport 35 min (10–190).

Analysis of risk factors for haemodynamic instability

Of the 67 patients, 14 (20.9%) had haemodynamic instability at the time of diagnosis. Table 3 presents the results of the univariate and multivariate analyses of risk factors. The only significant risk factor in the multivariate analysis was age 1 year or less, with the probability of having haemodynamic instability being 10-fold in this group compared to patients aged more than 1 year. In the multivariate analysis, male sex, a previous history of tachycardia and the presence of tachycardia at the time the transport team arrived to the referring hospital were not significant risk factors for haemodynamic instability. The mechanism of the tachycardia and the presence of Coumel’s tachycardia were not risk factors for haemodynamic instability either.

Table 3.

Analysis of risk factors for haemodynamic instability.

Variable  UnivariateMultivariate
  OR  LB of 95% CI  UB of 95% CI  P  OR  LB of 95% CI  UB of 95% CI  P 
Age ≤1 year  10.8  1.3  88.3  .004  10.2  1.2  89.9  .004 
Mechanism of tachycardia                 
Reentry tachycardia with short RP interval                 
Coumel’s type reentry tachycardia with long RP interval  1.8  0.2  22.0  .588  1.1  0.1  18.3  .926 
Automatic atrial tachycardia or fibrillation  0.5  0.1  4.7  .534  0.3  0.0  3.6  .513 
History of heart disease  0.7  0.1  6.9  .784  1.4  0.1  16.8  .954 
Previous episodes of PSVT  0.4  0.1  1.4  .134  0.6  0.1  2.8  .293 
Tachycardia when TT arrived to RH  2.5  0.8  8.5  .124  3.1  0.7  13.0  .114 
Male sex  1.2  0.4  3.9  .753  1.3  0.3  5.3  .949 

CI, confidence interval; LB, lower bound; OR, odds ratio; PSVT, paroxysmal supraventricular tachycardia; RH, referring hospital; TT, transport team; UB, upper bound.


This article is the first to present the experience of a paediatric transport team in the management of PSVT in the paediatric age group. There are articles in the literature on the prehospital management of adults with PSVT by paramedics,11 which is a different situation from the one analysed in our study.

Our findings show that PSVT corresponds to a small percentage of the total transports (about 1% of all interhospital transports). The predominant age groups were newborns, infants and toddlers, with no differences based on sex. Previous studies have reported an incidence of PSVT in children of 0.1%–0.4%,15 with a predominance of boys and onset before age 4 months.10 A relevant finding of our study is that 19.4% of patients had haemodynamic instability at the time of transport, with age equal or less than 1 year being the sole independent risk factor for this condition, with an OR of 10.2 (95% confidence interval, 1.2–89.9; p = 0.004), which demonstrates that adequate management of these patients may involve advanced life support throughout transport. Other possible risk factors like sex, pre-existing heart disease, a history of previous episodes, an electrical mechanism of tachycardia and whether the patient still had tachycardia when the TT arrived to the referring hospital were not statistically significant in our analysis.

The high percentage of patients with haemodynamic instability in our cohort may result from selection bias in our sample, as we only included patients that the RH decided to transfer to a specialised hospital, and it would be logical to assume that these were the most severely ill patients. The treatment patients received at the RH in transport did not deviate from published guidelines,15 and the transport team was able to maintain a sinus rhythm without recurrence of tachycardia in most patients, with no relevant complications and no deaths occurring during transport. Although previous studies have reported that the time elapsed from onset of tachycardia to reversion to sinus rhythm is associated with the risk of haemodynamic instability, the time of onset of tachycardia is often not known in children.

We ought to highlight that both the clinical diagnosis and treatment of the patients were mostly established by RHs. Decision-making by the TT predominated only in patients with haemodynamic instability in relation to the use of advanced life support measures like intubation or cardioversion. The time to stabilization and the duration of transport did not differ significantly from the corresponding median times recorded for the overall population served by our transport team.

As concerns the treatments used to terminate the tachycardia, we ought to highlight that only 29.7% of vagal manoeuvres were effective. In contrast, administration of adenosine was successful in 53% of cases. Patients received a median of 3 doses of adenosine. The mean initial dose of 100 µg/kg, but the mean effective dose was nearly twice as high. Guidelines on the management of PSVT in the neonatal period recommend initial doses of 50 µg/kg,16 but data from our study suggest that doses of less than 100 µg/kg are ineffective, so it seems appropriate to recommend an initial dose of 100 µg/kg and escalating to 200 and 300 µg/kg if the initial dose is not effective.

There is sufficient evidence in the literature,2 further supported by our findings, to recommend transport of all patients aged less than 1 year with a first episode of PSVT to a paediatric cardiology specialty centre for monitoring, assessment and treatment given the high percentage of patients in this age group that develop haemodynamic instability. Only in case of older children with tachycardia that reverts with basic measures it would be appropriate to refer the patient to an outpatient paediatric cardiology clinic with indications on when to seek attention at the RH and education on how to perform vagal manoeuvres,1,10 as is done with adult patients.8 None of the patients in our study met these criteria, and therefore the transfer was justified in every case.

Some of the limitations of our study are the selection bias implied in including patients requiring intrahospital transport by a specialised team and the difficulty in making a comprehensive evaluation of the outcomes of all transported patients due to the large number of receiving hospitals.


Transport of paediatric patients with PSVT to a tertiary care hospital is infrequent and may require highly specialised care, especially in infants aged 1 year or less. In our case series, 20% of patients had haemodynamic instability at the time of transport, the probability of which was 10.2 times greater in the group aged 1 year or less. Adequate management and treatment of these patients allows transport with maintenance of a sinus rhythm, which is associated with a lower morbidity and mortality.

Conflicts of interest

The authors have no conflicts of interest to declare.

C.R. Hanash, J.E. Crosson.
Emergency diagnosis and management of pediatric arrhythmias.
J Emerg Trauma Shock., 3 (2010), pp. 251-260
S.J. Doniger, G.Q. Sharieff.
Pediatric dysrhythmias.
Pediatr Clin North Am., 53 (2006), pp. 85-105
A. Quattrocelli, J. Lang, A. Davis, A. Pflaumer.
Age makes a difference: symptoms in pediatric supraventricular tachycardia.
J Arrhythm., 34 (2018), pp. 565-571
K.T. Kang, J.E. Potts, A.E. Radbill, M.J. La Page, J. Papagiannis, J.M. Garnreiter, et al.
Permanent junctional reciprocating tachycardia in children: a multicenter experience.
Heart Rhythm., 11 (2014), pp. 1426-1432
W.P. Walsh, B.C.I.J.K. Triedman.
Cardiac arrhythmias.
Nadas’ pediatric cardiology, 2nd ed.,
E. Umana, C.A. Solares, M.A. Alpert.
Tachycardia-induced cardiomyopathy.
Am J Med., 114 (2003), pp. 51-55
J. Brugada, N. Blom, G. Sarquella-Brugada, C. Blomstrom-Lundqvist, J. Deanfield, J. Janousek, et al.
European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement.
Europace., 15 (2013), pp. 1337-1382
J. Brugada, D.G. Katritsis, E. Arbelo, F. Arribas, J.J. Bax, C. Blomström-Lundqvist, et al.
ESC Scientific Document Group. 2019 ESC guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).
Moss and Adams’ heart disease in infants, children, and adolescents: including the fetus and young adults, pp. 309-313
Textbook of pediatric emergency medicine, 6th ed, pp. 702-717
M. Gausche, D.E. Persse, T. Sugarman, S.R. Shea, G.L. Palmer, R.J. Lewis, et al.
Adenosine for the prehospital treatment of paroxysmal supraventricular tachycardia.
Ann Emerg Med., 24 (1994), pp. 183-189
H. Clausen, T. Theophilos, K. Jackno, F.E. Babl.
Paediatric arrhythmias in the emergency department.
Emerg Med J., 29 (2012), pp. 732-737
S. Díaz-Parra, P. Sánchez-Yañez, I. Zabala-Argüelles, B. Picazo-Angelin, L. Conejo-Muñoz, V. Cuenca-Peiró, et al.
Use of adenosine in the treatment of supraventricular tachycardia in a pediatric emergency department.
Pediatr Emerg Care., 30 (2014), pp. 388-393
J.D. Losek, E. Endom, A. Dietrich, G. Stewart, W. Zempsky, K. Smith.
Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review.
Ann Emerg Med., 33 (1999), pp. 185-191
P. Vos, C.F. Pulles-Heintzberger, T. Delhaas.
Supraventricular tachycardia: an incidental diagnosis in infants and difficult to prove in children.
Acta Paediatr., 92 (2003), pp. 1058-1061
A.P. Green, K.H. Giattina.
Adenosine administration for neonatal SVT.
Neonatal Netw., 12 (1993), pp. 15-18

Please cite this article as: Sabaté Rotés A, Figueras Coll M, Gran Ipiña F, Gallardo-Calero A, Renter Valdovinos L, Domínguez-Sampedro P, et al. Taquicardia paroxística supraventricular desde la perspectiva del transporte interhospitalario. An Pediatr (Barc). 2020;93:236–241.

Copyright © 2020. Asociación Española de Pediatría
Anales de Pediatría (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.